Episode 4 in the Cutting Edge Conversation series featured Dr. Mujeebur Rahuman, Dr. Holger von Moeller, and Dr. Fernando Huerta as they discuss about industry challenges and innovations surrounding Chemical, Manufacturing and Controls in the life sciences industry.
During the course of the webinar a variety of emerging topics regarding chemicals, manufacturing and controls were discussed. Presenters spoke about RNA based therapies, and biologics, with a focus on the clinical development process of these new methodologies. They examined Investigational New Drug submission, which is one of the bottlenecks facing industry professionals, and  discussed how to accelerate that process as a component of Good Manufacturing Practice. The presenters expanded upon current topics such as manufacturing and controls for vaccines as well as new formulation techniques and solid state crystal forms. The group Q&A session provided all attendees with an opportunity to question these experts on any of these topics.
Presenters
M.S.M. Mujeebur Rahuman
Mujeebur Rahuman has two decades of expertise in handling NCE process development, CRAMS, generic API development, DMF filing, technology development, innovation and cGMP manufacturing projects.
Holger von Moeller
In conjunction with his partner Dr. Bernhard Loll, Dr. Holger von Moeller founded moloX in 2012 to provide highly pure proteins for pharmaceutical, biochemical, biotechnological, and academic research.
Fernando Huerta
In late 2015 Fernando started a new adventure as Freelancer researcher and chemical information systems consultant. Fernando F. Huerta is now Researcher and Project Leader at RISE Bioscience & Materials, SE
Sponsor
Aragen
MOLOX
Research Institutes of Sweden
Content Partners
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
